论文部分内容阅读
目的研究血清乳酸脱氢酶与非霍奇金淋巴瘤分期及生存期关系。方法对１５６例非霍奇金淋巴瘤患者进行血清乳酸脱氢酶检测。结果局限期（Ⅰ＋Ⅱ）患者血清乳酸脱氢酶异常增高（指血清乳酸脱氢酶大于或等于正常值高限的１．５倍）为５０．０％（２７／５４）；中晚期（Ⅲ＋Ⅳ）患者血清乳酸脱氢酶异常增高为６８．６％（７０／１０２），而以中晚期患者血清乳酸脱氢酶异常增高为普遍（Ｐ＜０．０５）。Ⅰ、Ⅱ期患者随访１～５年，血清乳酸脱氢酶不增高组的５年预期存活率均为１００％；血清乳酸脱氢酶异常增高组的５年预期存活率分别为９５．６％，８０．９％，８０．９％，８０．９％８０．９％，经Ｋａｐｌａｎ－Ｍｅｉｅｒ分析两组生存期有显著性差别（Ｐ＜０．０５）。Ⅲ、Ⅳ期患者随访１～５年，血清乳酸脱氢酶不增高组的５年预期存活率均为１００％；血清乳酸脱氢酶异常增高组的５年预期存活率分别为７９．８％，６６．９％，５５．７％，４８．１％，４８．１％，两组生存期差别有显著性（Ｐ＜０．０２）。结论血清乳酸脱氢酶与非霍奇金淋巴瘤分期及生存期有关，可作为预测非霍奇金淋巴瘤分期及生存期的重要因素
Objective To study the relationship between serum lactate dehydrogenase and stage and survival of non-Hodgkin’s lymphoma. Methods Serum lactate dehydrogenase was detected in 156 patients with non-Hodgkin’s lymphoma. Abnormal elevation of serum lactate dehydrogenase in patients with limited results (I+II) (refers to serum lactate dehydrogenase is greater than or equal to 1.5 times the upper limit of normal) is 50.0% (27/54); middle-late (III+IV) The abnormal increase of serum lactate dehydrogenase was 68.6% (70/102), and the abnormal increase of serum lactate dehydrogenase was common in patients with advanced and advanced disease (P<0.05). Stage I and II patients were followed up for 1 to 5 years. The 5-year expected survival rate for the serum lactate dehydrogenase-free group was 100%, and the 5-year expected survival rate for the serum lactate dehydrogenase abnormality-increased group was 95.6%. , 80.9%, 80.9%, 80.9% and 80.9%, the Kaplan-Meier analysis showed significant difference in survival between the two groups (P<0.05). During the 1- to 5-year follow-up of patients with stage III and IV, the 5-year expected survival rate of the serum lactate dehydrogenase-free group was 100%; the 5-year expected survival rate of the serum lactate dehydrogenase abnormally-high group was 79.8%. , 66.9%, 55.7%, 48.1%, 48.1%, the difference in survival between the two groups was significant (P < 0.02). Conclusions Serum lactate dehydrogenase is related to the stage and survival of non-Hodgkin’s lymphoma and can be used as an important predictor of stage and survival of non-Hodgkin’s lymphoma.